Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

503
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
503
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

2.8K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
2.8K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

539
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
539
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

13.3K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.3K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

766
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
766

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variability in hypoxic response: Could genetics play a role?

The Journal of physiology·2020
Same author

Effect of Venlafaxine on Apnea-Hypopnea Index in Patients With Sleep Apnea: A Randomized, Double-Blind Crossover Study.

Chest·2020
Same author

Is Umbilical Cord Blood Therapy an Effective Treatment for Early Lung Injury in Growth Restriction?

Frontiers in endocrinology·2020
Same author

Driving Pressure for Ventilation of Patients with Acute Respiratory Distress Syndrome.

Anesthesiology·2020
Same author

Pathogenesis of obstructive sleep apnea in individuals with the COPD + OSA Overlap syndrome versus OSA alone.

Physiological reports·2020
Same author

Contemporary Concise Review 2019: Sleep and ventilation.

Respirology (Carlton, Vic.)·2020

Related Experiment Video

Updated: Dec 11, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.1K

ACE2, Metformin, and COVID-19.

Atul Malhotra1, Mark Hepokoski2, Karen C McCowen3

  • 1Department of Medicine, University of California, San Diego, La Jolla, CA 92023, USA; Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, La Jolla, CA 92023, USA.

Iscience
|August 21, 2020
PubMed
Summary

Metformin, an anti-diabetic drug, may protect the heart and lungs in COVID-19 by increasing Angiotensin converting enzyme 2 (ACE2) expression. This offers a potential rapid treatment option for COVID-19 patients.

Keywords:
EndocrinologyVirology

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.0K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

Related Experiment Videos

Last Updated: Dec 11, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

3.1K
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.0K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

Area of Science:

  • Cardiovascular and Pulmonary Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • COVID-19 is a leading global cause of mortality with limited effective therapies.
  • Angiotensin converting enzyme 2 (ACE2) plays a critical role in COVID-19 pathogenesis, mediating viral entry via SARS-CoV-2 spike protein binding.
  • ACE2 regulates the protective arm of the renin-angiotensin-aldosterone system (RAAS), offering anti-hypertensive and anti-inflammatory effects.

Purpose of the Study:

  • To explore the potential of metformin as a cardiopulmonary protective therapy for COVID-19.
  • To investigate whether metformin can enhance ACE2 expression, counteracting SARS-CoV-2-induced downregulation.
  • To address the urgent need for effective COVID-19 treatments while novel therapies are developed.

Main Methods:

  • Review of preclinical and clinical data on metformin's effects.
  • Analysis of metformin's proposed mechanism involving ACE2 modulation.
  • Evaluation of metformin's safety profile as an established anti-diabetic agent.

Main Results:

  • Preclinical data suggest SARS-CoV-2 binding may downregulate ACE2, potentially leading to cardiopulmonary injury.
  • Metformin, an accessible anti-diabetic drug with a strong safety record, is indicated to enhance ACE2 expression.
  • This enhancement by metformin may confer cardiopulmonary protection in the context of COVID-19.

Conclusions:

  • Metformin presents a promising therapeutic candidate for mitigating COVID-19-related cardiopulmonary complications.
  • Targeting ACE2 expression with existing, safe medications like metformin could provide an urgently needed treatment strategy.
  • Further clinical investigation is warranted to confirm metformin's efficacy and safety in COVID-19 patients.